Department of Neurosurgery, University of Pittsburgh Medical Center, 200 Lothrop Street, 4th floor, Pittsburgh, PA, USA.
Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL, USA.
Transl Stroke Res. 2024 Oct;15(5):936-940. doi: 10.1007/s12975-023-01179-9. Epub 2023 Jul 20.
Maladaptive inflammation underlies the formation and rupture of human intracranial aneurysms. There is a growing body of evidence that anti-inflammatory pharmaceuticals may beneficially modulate this process. Clopidogrel (Plavix) is a commonly used irreversible P2Y12 receptor antagonist with anti-inflammatory activity. In this paper, we investigate whether clopidogrel is associated with the likelihood of aneurysm rupture in a multi-institutional propensity-matched cohort analysis. Patients presenting for endovascular treatment of their unruptured intracranial aneurysms and those presenting with aneurysm rupture between 2015 and 2019 were prospectively identified at two quaternary referral centers. Patient demographics, comorbidities, and medication usage at the time of presentation were collected. Patients taking clopidogrel or not taking clopidogrel were matched in a 1:1 fashion with respect to location, age, smoking status, aneurysm size, aspirin usage, and hypertension. A total of 1048 patients with electively treated aneurysms or subarachnoid hemorrhages were prospectively identified. Nine hundred twenty-one patients were confirmed to harbor aneurysms during catheter-based diagnostic angiography. A total of 172/921 (19%) patients were actively taking clopidogrel at the time of presentation. Three hundred thirty-two patients were matched in a 1:1 fashion. A smaller proportion of patients taking clopidogrel at presentation had ruptured aneurysms than those who were not taking clopidogrel (6.6% vs 23.5%, p < .0001). Estimated treatment effect analysis demonstrated that clopidogrel usage decreased aneurysm rupture risk by 15%. We present, to the best of our knowledge, the first large-scale multi-institutional analysis suggesting clopidogrel use is protective against intracranial aneurysm rupture. It is our hope that these data will guide future investigation, revealing the pathophysiologic underpinning of this association.
适应性炎症是人类颅内动脉瘤形成和破裂的基础。越来越多的证据表明,抗炎药物可能有益地调节这一过程。氯吡格雷(Plavix)是一种常用的不可逆 P2Y12 受体拮抗剂,具有抗炎活性。在本文中,我们通过多机构倾向匹配队列分析研究氯吡格雷与颅内动脉瘤破裂的可能性之间的关系。前瞻性地在两个四级转诊中心确定因未破裂颅内动脉瘤就诊并于 2015 年至 2019 年期间因动脉瘤破裂就诊的患者。收集患者的人口统计学、合并症和就诊时的药物使用情况。以位置、年龄、吸烟状况、动脉瘤大小、阿司匹林使用和高血压为基础,以 1:1 的比例匹配服用氯吡格雷或不服用氯吡格雷的患者。共前瞻性地确定了 1048 例择期治疗的动脉瘤或蛛网膜下腔出血患者。921 例患者在基于导管的诊断性血管造影期间被证实存在动脉瘤。172/921(19%)例患者在就诊时正在服用氯吡格雷。332 例患者以 1:1 的比例匹配。就诊时服用氯吡格雷的患者中破裂动脉瘤的比例明显低于未服用氯吡格雷的患者(6.6%比 23.5%,p<0.0001)。估计治疗效果分析表明,氯吡格雷的使用使动脉瘤破裂风险降低了 15%。据我们所知,这是首次大规模多机构分析表明氯吡格雷的使用可预防颅内动脉瘤破裂。我们希望这些数据将指导未来的研究,揭示这种关联的病理生理基础。